Key takeaway: During the Q1 FY27 earnings conference call held on August 7, 2026, management reported a 12% year-over-year revenue growth, driven by a 26% increase in the CRO segment. Management expressed confidence in the company's growth trajectory, highlighting the importance of expanding capacity in the second half of the year. They noted that geopolitical factors have made India a key player in clients' diversification strategies. The company is transitioning from a small molecule CRDMO to a technology-led, multi-modality partner, with significant investments in R&D and new capabilities, particularly in peptides and formulation. The CFO, Siva Chittor, reported a healthy balance sheet and emphasized the importance of long-term relationships with clients, with over 90% of revenue coming from returning customers. Management set a long-term revenue growth goal of 15% to 20% and an EBITDA range of 28% to 30%.

Key takeaway: Sai Life Sciences Limited reported a revenue of ₹554 crore for Q1 FY27, reflecting a 12% year-on-year growth. The company's CRO segment grew by 24% year-on-year, while the CDMO segment contributed to a healthy balance sheet with a material margin of ₹409 crore, up 15% year-on-year. Management highlighted the importance of integrated service delivery, noting that 65% of customers engaged in such collaborations. The company has 33 active commercial molecules and 14 late-phase molecules in its CMC pipeline. Management set a goal of sustaining long-term revenue growth of 15-20% and an EBITDA margin of 28-30%. Additionally, Sai Life Sciences achieved an EcoVadis Platinum Rating for sustainability, placing it among the top 1% of assessed companies globally. The presentation emphasized the company's commitment to innovation and expansion in next-generation modalities, including peptides and ADCs.

Key takeaway: Sai Life Sciences Limited submitted a transcript of its earnings call for the audited financial results for the quarter and year ended 31 March 2026. The earnings call took place on 15 May 2026 at 04:00 PM IST. The document was filed with the National Stock Exchange of India and BSE Limited, and it is available on the company's website. Runa Karan, the Company Secretary and Compliance Officer, signed the document digitally.

Key takeaway: Sai Life Sciences Limited reported significant growth in its investor presentation for the fiscal year ending March 31, 2026. The company achieved a revenue of ₹2,192 crore, marking a 29% increase from ₹1,695 crore in FY25. EBITDA rose to ₹661 crore, a 56% increase year-over-year, with an EBITDA margin of 30%. The presentation highlighted the company's strategic focus on deepening relationships with global pharma customers and expanding its integrated CRDMO capabilities. Management indicated a planned capital expenditure of ₹1,100-1,300 crore for FY27, aimed at aligning with customer demand and long-term growth opportunities. The document also noted the establishment of a high-throughput experimentation platform and advancements in next-generation technologies. Despite ongoing geopolitical tensions affecting input costs, management reported no significant impact on operations from the evolving tariff environment.

Key takeaway: Sai Life Sciences Limited submitted a transcript of its earnings call for the unaudited financial results for the quarter and nine months ended 31 December 2025. The earnings call took place on 6 February 2026 at 04:00 PM IST. The document was filed in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015, and is available on the company's website. Runa Karan, the Company Secretary and Compliance Officer, signed the document digitally.

Key takeaway: Sai Life Sciences Limited reported its investor presentation for the third quarter and nine months ended December 31, 2025. Management highlighted continued progress in establishing the company as a globally relevant Contract Research, Development, and Manufacturing Organization (CRDMO). The presentation noted a 27% year-on-year increase in total revenue to ₹556 crore, with EBITDA growing by 54% to ₹191 crore. The company emphasized its capacity expansion plans, having invested ₹405 crore in capital expenditure aligned with a ₹700 crore plan for FY26. Management reported strong growth in both the Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments, with significant contributions from large pharmaceutical clients. The document also outlined ongoing investments in technology and infrastructure to support future growth and innovation.